| Today’s Big NewsFeb 6, 2024 |
| By Fraiser Kansteiner Rumblings of a potential bidding war over cancer specialist MorphoSys have subsided as quickly as they arose after Novartis descended on the German biotech Monday with billions of dollars in cash. The move comes less than 24 hours after rumors of the M&A imbroglio surfaced in Reuters. |
|
|
|
By Gabrielle Masson Set the bar and then beat it; that's what Vertex Pharmaceuticals has just done with a next-gen cystic fibrosis treatment. |
By Max Bayer Kyverna is upping its planned IPO by about $100 million, now looking to net a little under $300 million. The cell therapy biotech has repriced its shares between $20 to $21. |
Sponsored by ICON In this exclusive interview, ICON Biotech President Chris Smyth paints a picture of the operating environment facing biotechs in 2024. |
|
Tissue, biofluids, cellular preparations and more from ANY commercially available species, all from one source: BioIVT. Learn More >>
|
|
By Nick Paul Taylor Eli Lilly has axed its next-generation RET inhibitor. The Big Pharma pushed the candidate, LOXO-260, into the clinic to overcome acquired resistance to existing drugs such as its own Retevmo but has now pulled it from the pipeline before clearing phase 1. |
By Nick Paul Taylor Rallybio is shedding weight for the next leg of its race, parting ways with 45% of its staff and focusing on its two phase 2-ready programs to extend its cash runway into the middle of 2026. |
By James Waldron Barely two months after SpringWorks Therapeutics secured the first ever FDA approval for a drug to treat ultra-rare desmoid tumors, Immunome has bagged the rights to a phase 3 therapy it thinks could be more effective. |
By Helen Floersh Gain Therapeutics’ phase 1 drug for Parkinson’s disease associated with a common gene mutation appears to restore motor function in mice, even after a relatively long delay between symptom onset and treatment, new data from the company shows. |
By Helen Floersh Colorectal cancer used to be considered a disease of the aged, but rising rates among younger adults have left physicians and scientists scratching their heads. Now, a new study hints that populations of gut bacteria might be playing a role. |
By Fraiser Kansteiner Locked in a heated battle with Novo Nordisk’s semaglutide franchise, Eli Lilly’s tirzepatide is beginning to come into its own—both with regards to sales and amid attempts to show the dual GIP/GLP-1 agonist can strike out beyond diabetes and obesity. |
By Angus Liu Eli Lilly's star diabetes and weight loss drug tirzepatide showed promise in fatty liver disease, with its massive anti-MASH benefit accompanied by a "clinically meaningful" anti-fibrosis effect. |
By Andrea Park An app developed by Cedars-Sinai for use with Apple’s new spatial computing headset is putting a new spin on the concept of virtual care. |
By Nick Paul Taylor Sanofi is stepping up support for employees with cancer and other critical illnesses, agreeing to secure their jobs, salaries and benefits for at least 12 months after diagnosis regardless of their location or role. |
Fierce podcastsDon’t miss an episode |
| | This week on “The Top Line,” Fierce’s Conor Hale interviews Peter Shen, the North American head of digital health at Siemens Healthineers, to explore what developers and regulators can do to ensure transparency in medical AI. He also dives into how the field could potentially benefit from a 21st-century update to the Hippocratic Oath. |
|
|---|
|
|
|
Stability and particle formation are key variables across the lifecycle. New instruments that improve measurement are transforming testing and becoming necessary. Download this essential reading now for biopharma companies that want to understand how particle detection is evolving and the value new technologies provide across the lifecycle.
|
|
| Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
